secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-037962
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx Q2 2023 revenue $108.3M (+21% YoY); reaffirms 2023 guidance
----------------------------------------------------------------------

- Q2 total revenue $108.3M vs $89.3M YoY; Crysvita $83.0M (+20%), Dojolvi $16.5M, Mepsevii $8.4M.
- Net loss $159.8M ($2.25/sh) compared to $158.2M ($2.26) in Q2 2022; cash and equivalents $618.4M.
- Reaffirmed FY2023 guidance: total revenue $425-450M, Crysvita $325-340M, Dojolvi $65-75M.
- Setrusumab Phase 2 OI data: 9.4% BMD increase at 20mg/kg in 3 months; Phase 3 Orbit/Cosmic enrolling.
- Howard Horn appointed CFO and EVP Corporate Strategy effective Oct 16, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023037962/0000950170-23-037962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023037962/rare-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer